Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017
Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Endogenous mu-opioid modulation of social connection in humans: a systematic review and meta-analysis.Translational psychiatry · 2024Pooled it
- Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals.Molecular psychiatry · 2020Trial
- Oxytocin Reduces Alcohol Cue-Reactivity in Alcohol-Dependent Rats and Humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- Review
- Validation ofInternational journal of molecular sciences · 2025Article
- Methodological considerations for interpreting ketamine-naltrexone trials in depression.The international journal of neuropsychopharmacology · 2025Article
- The Neuropathology of Alcohol Use Disorder: Cellular Insights From Human Post-Mortem Studies.Journal of neurochemistry · 2025Review
- Opioid Regulation of Social Homeostasis: Connecting Loneliness to Addiction.Biological psychiatry · 2025Review
- The Dopamine System in Mediating Alcohol Effects in Humans.Current topics in behavioral neurosciences · 2025Review
- Molecular Imaging Studies of Alcohol Use Disorder.Current topics in behavioral neurosciences · 2025Review
- Cholinergic mu-opioid receptor deletion alters reward preference and aversion-resistance.Neuropharmacology · 2024Article
- The influence of drug class on reward in substance use disorders.Pharmacology, biochemistry, and behavior · 2024Review
- The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder.Current medicinal chemistry · 2024Review
- Hazardous drinking and alcohol use disorders.Nature reviews. Disease primers · 2022Review
- Risk for opioid misuse in chronic pain patients is associated with endogenous opioid system dysregulation.Translational psychiatry · 2022Article
- Alcohol and the Brain.Nutrients · 2021Review
- Early Life Stress and Risks for Opioid Misuse: Review of Data Supporting Neurobiological Underpinnings.Journal of personalized medicine · 2021Review
- Dysregulation of the histone demethylase KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways.Addiction biology · 2021Article
- Nicotine increases alcohol self-administration in male rats via a μ-opioid mechanism within the mesolimbic pathway.British journal of pharmacology · 2020Article
- Neuroendocrine effects of naltrexone versus nalmefene in humans.Human psychopharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Blockade of the μ-opioid receptor (MOR) by naltrexone reduces relapse risk in a subpopulation of alcohol-dependent patients. Previous positron-emission-tomography (PET) studies using the MOR ligand [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.